AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit approved by Chinese Authority
AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit was approved by Chinese National Medical Products Administration (NMPA) on February 27, 2019, intended for qualitative detection of gene BRCA1 and BRCA2 mutation in patients with different cancer types
Welcome to visit AmoyDx on 17th Congress on Targeted Anticancer Therapies (TAT) in Paris
The 17th Congress on Targeted Anticancer Therapies started in Paris on 25 February, 2019. The three-day congress will be a good opportunity to shape the future of oncology drug product development together with the world’s most renowned experts.
Sanomics Limited and Amoy Diagnostics Partner to Deliver Multi-Gene Tests in Hong Kong and Macau
Xiamen, 28 January 2019 – Amoy Diagnostics Co., LTD., a leading company focusing on molecular diagnostics for precision oncology, and Sanomics Limited, a pioneering company in providing genomics tests in
AmoyDx ROS1 Kit Approval in Taiwan
Recently AmoyDx ROS1 gene fusion detection kit (fluorescence PCR method) was approved by Taiwan Food and Drug Administration(TFDA).
AmoyDx® Essential NGS panel approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
2018 AmoyDx Distributors Annual Meeting successfully held in Shanghai
November 11, 2018 (Shanghai, China) AmoyDx Distributors Annual Meeting 2018 was held in Shanghai on November 8, 2018. 34 delegates from 19 countries gathered together to get the latest market